Fluicell

Fluicell Total Assets

The Total Assets of Fluicell (FLUI.ST) as of Nov 1, 2026 is 18.48 M SEK. In the previous year, Total Assets was 25.51 M SEK — a change of -27.57% (lower).

Total Assets

18.48 MSEK

YoY

-27.57%

Last updated:

Total Assets of Fluicell is 2025 18.48 M SEK. Total Assets of Fluicell was 2024 25.51 M SEK. It decreases by -27.57% lower compared to the previous year.

The Fluicell Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2018
25.97 M SEK
Jan 1, 2019
19.94 M SEK
Jan 1, 2020
24.83 M SEK
Jan 1, 2021
26.98 M SEK
Jan 1, 2022
31.77 M SEK
Jan 1, 2023
9.34 M SEK
Jan 1, 2024
25.51 M SEK
Jan 1, 2025
18.48 M SEK
The Fluicell Total Assets history
YEARTotal AssetsYoY
18.48 MSEK-27.57%
25.51 MSEK+173.10%
9.34 MSEK-70.60%
31.77 MSEK+17.73%
26.98 MSEK+8.66%
24.83 MSEK+24.54%
19.94 MSEK-23.24%
25.97 MSEK+125.17%
11.54 MSEK+315.68%
2.78 MSEK+62.66%
1.71 MSEK+2.04%
1.67 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Fluicell Stock analysis

What does Fluicell do? Fluicell AB commercializes research tools BioPen and Dynaflow Resolve for studying, processing, and measuring drug impact on individual cells in cell-based pharmacology research. The company also develops bioprinting technology Biopixlar Retina, offering 2D and 3D options to create complex tissue-like structures with precise cell positioning control. These products target drug development research segments where individual cell analysis is critical. The primary buyers are pharmaceutical companies and research institutions focused on cell-based pharmacology. Fluicell AB's product portfolio includes BioPen, Dynaflow Resolve, and Biopixlar Retina, all designed for cell-based pharmacology research applications. The company's tools enable detailed analysis of drug effects at the single-cell level, supporting pharmaceutical research and development processes. Biopixlar Retina specifically addresses tissue engineering needs by allowing controlled creation of tissue-like structures in both 2D and 3D formats. The company's revenue streams come from selling these research tools and bioprinting technologies to pharmaceutical companies and research institutions. These segments value the precision and control offered by Fluicell's products for cell-based drug development studies. The products are positioned as essential tools for advanced cell analysis in pharmacology research environments. Fluicell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fluicell stock

Total Assets of Fluicell is 18.48 M SEK in 2025.

Total Assets of Fluicell changed from 25.51 M SEK to 18.48 M SEK, representing a -27.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets Fluicell since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's Fluicell historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Fluicell

All Key Metrics — Fluicell